Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon)

NCT ID: NCT04857970

Last Updated: 2021-04-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-20

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Routine electronic monitoring of health-related quality of life (REMOQOL) consists of collecting HRQoL patients' data via an electronic device in order to provide these data to healthcare providers. Collected data could be used by professionals to personalize care through for instance, orientation towards personalized supportive care; assessment of toxicities related to treatments or adapted treatments.

The aim of this study is to investigate the impact of REMOQOL on the care relationship in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are naïve for systemic treatment. To do this, the investigators want to conduct a randomized trial at the Besançon University Hospital.

Several teams are collaborating on this project: Methodology and Quality of Life Unit in Oncology (UMQVC), pneumonology and medical oncology services of the Besançon University Hospital and psychology laboratories of Franche-Comté and Burgundy Universities.

The original aspects of this research are the particular interest in the care relationship between physicians and patients, also taking an interest in the physician's experience, the strong collaboration with researchers in psychology, the use of mixed quantitative and qualitative analysis techniques as well as the design of randomized study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

REMOQOL-Poumon is an interventional, prospective, randomized study, conducted in Besançon University Hospital. Patients are randomized whether in the experimental arm or in the control arm. Intervention in experimental arm consists of administration of HRQoL questionnaires (QLQ-C30 \& QLQ-LC13) using the CHES software (Computer-based Health Evaluation System) and presentation of the HRQoL scores to physicians via colored graphics.

In control arm, HRQoL questionnaires (QLQ-C30+LC13) are administered in a paper-pencil way, without transmission of results to physicians.

Patients are followed for four encounters with HRQoL collection. The primary outcome, measured with the AREP questionnaire, is assessed after those four encounters.

At the end of the follow-up, a semi-structured interview with a researcher in psychology and concerning the care relationship is proposed to a sub-cohort of patients (around ten patients in each arm).

After each encounter, physicians are asked to answer a questionnaire on viewing and use of HRQoL scores. Every physician will be interviewed on care relationship by a researcher in psychology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Electronic HRQoL questionnaires with feedback to physicians

40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.

Electronic HRQoL questionnaires with feedback to physicians

Intervention Type OTHER

Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians

Paper-pencil HRQoL questionnaires w.o. feedback to physician

40 patients allocated in this arm will answer HRQOL questionnaires using "pencil-paper", without transmission of the HRQoL scores to physicians.

Paper-pencil HRQoL questionnaires w.o. feedback to physicians

Intervention Type OTHER

Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic HRQoL questionnaires with feedback to physicians

Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians

Intervention Type OTHER

Paper-pencil HRQoL questionnaires w.o. feedback to physicians

Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient diagnosed with locally advanced or metastatic non-small cell lung cancer
* Patients treated at University Hospital of Besançon
* No prior systemic therapy for cancer
* Males and Females, age ≥18 years old
* Patient able to complete the HRQoL questionnaires
* Patients who gave their informed consent to participate.


* Patients who realized 4 clinical encounters with collection of HRQoL
* For patients from experimental arm, the physician must have checked HRQoL results


• Any physician treating patients included in the study REMOQOL-Poumon

Exclusion Criteria

* Patients with tumor recurrence
* Patients receiving oral antineoplastic therapy for whom at least monthly follow-up is not feasible
* Patients with psychopathology or serious cognitive problems
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Franche-Comté

OTHER

Sponsor Role collaborator

University of Burgundy

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Virginie WESTEEL, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CHU de Besançon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Besançon

Besançon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sophie PAGET BAILLY, PhD

Role: CONTACT

0033370632176

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sophie Paget-Bailly, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P/2018/391

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CAncer, NUtrition and Taste 2
NCT05027490 COMPLETED NA